Abbott Laboratories Corporation

Abbvie Inc.

Abbvie Bahamas Limited

Makoto, Aoyama

Michael R Michaelides

Steven K Davidsen

Yan Guo

Alan S Florjancic

James H Holms

Robin R Frey

Zhiqin Ji

Douglas H Steinman

George S Sheppard

Michael L Curtin

Yujia Dai

Stevan Wakefield Djuric

Anna M Ericsson

David John Augeri

David A Betebenner

Gavin C Hirst

Kent D Stewart

Stephen W Fesik

Alan Frank Gasiecki

James B Summers, Jr

Yufeng Hong

Keith W Woods

Richard W Dixon

Joseph F Dellaria, Jr

David J Calderwood

Paul Rafferty

Jianchun Gong

Irini Akritopoulou-Zanze

Sheela A Thomas

Howard Robin Heyman

Richard A Craig

Philip J Hajduk

Henry Q Zhang

Carol K Wada

Kresna Hartandi

Paul P Ehrlich

Zhiren Xia

Lianhong Xu

Jamie R Stacey

Heather M Davis

Maureen Ann McLaughlin

Vijaya J Gracias

Melanie A Muckey

Irini Zanze

David G Nettesheim

John W Kebabian

Robert W Schoenleber

Jürgen Dinges

Richard W McCroskey

Michael P DeNinno

Celerino Abad-Zapatero

Jamie R Giesler-Stacey

Chi-Nung Hsaio

Jamie R Giesler

Ji Zhiqin

William J Mcclellan

Howard R Heyman

Patrick Betschmann

Andrew F Burchat

Peter Hrnciar

Lee D Arnold

Aoyama Makoto

Kimba Fischer

Reverse hydroxamate inhibitors of matrix metalloproteinases

Inhibitors of matrix metalloproteinases

C-terminal compounds of formula ##STR1## are potent inhibitors of matrix metalloproteinase and are useful in the treatment of diseases in which matrix metalloproteinase play a role. Also disclosed are matrix metalloproteinase inhibiting compositions and a method of inhibiting matrix metalloproteinase in a mammal.

C-terminal ketone inhibitors of matrix metalloproteinases and TNF.alpha.

Macrocyclic compounds of formula ##STR1## are potent inhibitors of matrix metalloproteinase and are useful in the treatment of diseases in which matrix metalloproteinase play a role. Also disclosed are matrix metalloproteinase inhibiting compositions and a method of inhibiting matrix metalloproteinase in a mammal.

Macrocyclic inhibitors of matrix metalloproteinases and TNF.alpha.

The present invention relates to COX-2 inhibitors of the formula: ##STR1## wherein, A=halogen, C.sub.1 -C.sub.6 alkyl, SR.sup.1 or OR.sup.1 ;

Heterocyclic compounds as COX-2 inhibitors

A process for preparing a chiral tetracyclic compound of formula: ##STR1## wherein R is hydrogen or a C.sub.1 -C.sub.6 -alkyl group and Z is oxygen, sulfur or --CH.dbd.CH--, the compounds having uses as dopamine agonists. The process involves reacting a chiral starting material and subsequent chiral intermediates in a series of chirality-preserving synthetic reactions.

Process for preparing chiral tetracyclic dopaminergic compounds

A tetracyclic compound of the formula: ##STR1## wherein A and the atoms to which it is attached and the optional double bond represent a mono- or di-heterocyclic ring selected from: ##STR2## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and X are specifically defined, which compounds are useful in the treatment of dopamine-related neurological, psychological and cardiovascular disorders as well as in the treatment of substance abuse and other addictive behavior disorders, cognitive impairment and attention deficit disorder.

Tetracyclic compounds as dopamine agonists

Novel compounds of Formula (I): ##STR1## or pharmaceutically acceptable salts, esters and amides thereof, wherein A is O, C, CH or CH.sub.2, n is 0 or 1, and the dotted line is a single bond when A is O or CH.sub.2 and a double bond when A is CH or when n=0, A is C and

Dopaminergic compounds

Growing community of inventors

Gurnee, IL, United States of America

Michael R Michaelides